Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $139.25 Average Price Target from Analysts

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been given an average recommendation of “Moderate Buy” by the twenty-two research firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $139.67.

A number of research firms have recently commented on NBIX. The Goldman Sachs Group upped their price target on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. Citigroup dropped their target price on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a research note on Thursday, February 8th. StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Wedbush reiterated an “outperform” rating and issued a $147.00 price target on shares of Neurocrine Biosciences in a report on Wednesday. Finally, JPMorgan Chase & Co. raised their price objective on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th.

Neurocrine Biosciences Stock Down 0.4 %

NBIX stock opened at $132.00 on Monday. Neurocrine Biosciences has a twelve month low of $89.04 and a twelve month high of $148.37. The stock has a market capitalization of $13.14 billion, a price-to-earnings ratio of 54.55 and a beta of 0.25. The firm’s fifty day simple moving average is $136.15 and its two-hundred day simple moving average is $126.99.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The business had revenue of $515.20 million for the quarter, compared to analysts’ expectations of $518.52 million. During the same quarter in the previous year, the business posted $0.88 earnings per share. The business’s revenue was up 25.0% compared to the same quarter last year. As a group, equities research analysts expect that Neurocrine Biosciences will post 4.84 EPS for the current year.

Insider Transactions at Neurocrine Biosciences

In related news, CEO Kevin Charles Gorman sold 2,707 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $140.69, for a total transaction of $380,847.83. Following the completion of the transaction, the chief executive officer now owns 502,188 shares in the company, valued at approximately $70,652,829.72. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Kevin Charles Gorman sold 2,707 shares of the business’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total transaction of $380,847.83. Following the transaction, the chief executive officer now directly owns 502,188 shares in the company, valued at approximately $70,652,829.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Richard F. Pops sold 15,000 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total value of $1,987,050.00. Following the transaction, the director now owns 29,512 shares in the company, valued at $3,909,454.64. The disclosure for this sale can be found here. Insiders have sold a total of 196,994 shares of company stock valued at $27,205,009 in the last 90 days. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NBIX. Mather Group LLC. purchased a new position in Neurocrine Biosciences during the 1st quarter worth $26,000. Acadian Asset Management LLC purchased a new position in Neurocrine Biosciences during the 1st quarter worth $27,000. Headinvest LLC purchased a new position in Neurocrine Biosciences during the 3rd quarter worth $28,000. Lindbrook Capital LLC grew its stake in Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after buying an additional 96 shares during the last quarter. Finally, EdgeRock Capital LLC purchased a new position in Neurocrine Biosciences during the 4th quarter worth $31,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.